Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Marginal Zone Lymphoma: early-phase trial registry
28 of 50 indexed Marginal Zone Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #277 of 28,707 conditions by registered trial count.
50 US clinical trials · 28 currently recruiting · #277 of 28,707 conditions by registered trial count
Marginal Zone Lymphoma: 50 US clinical trials tracked, 28 recruiting.
Marginal Zone Lymphoma is the subject of 50 registered US clinical trials on ClinicalTrials.gov, 28 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition marginal-zone-lymphoma
OPEN 28 | RECR 56% | LATE 4 | EARLY 43 | RANK #277 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Celiac Disease (56% recruiting · 25 trials)
Marginal Zone Lymphoma lists 28 open slots (56% of 50 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Marginal Zone Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Marginal Zone Lymphoma is recruiting above its size-band peers.
28 of 50 indexed trials (56%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Marginal Zone Lymphoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 4 of 50 trials (8%). 42 distinct sponsors appear on at least one study for this condition label.
-
Most Marginal Zone Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 50 trials that report a genuine target (sentinel values excluded). 37 of those (74%) plan for fewer than 100 participants.
-
Marginal Zone Lymphoma research is mostly interventional.
48 interventional and 2 observational studies make up this index (96% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
50 total, page 1 of 1
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
BeiGene
NCT05100862
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05006716
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Memorial Sloan Kettering Cancer Center
NCT07029217
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
NCT05643742
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences
NCT05602363
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT04186520
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Mayo Clinic
NCT06151730
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Enterome
NCT04669171
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center, University of Minnesota
NCT06792825
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical
NCT04775745
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Brown University
NCT04792502
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
University of Miami
NCT05296070
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT04883437
Epco, Zanu, Ritux for R/R FL or MZL
Reid Merryman, MD
NCT06563596
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
NCT06350318
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech
NCT05653271
64Cu-LLP2A for Imaging Hematologic Malignancies
Washington University School of Medicine
NCT06636175
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
UNC Lineberger Comprehensive Cancer Center
NCT06860880
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Gottfried von Keudell, MD PhD
NCT06510309
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics
NCT06533579
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT05281809
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
NCT06300528
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Izidore Lossos, MD
NCT06796998
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
University of Utah
NCT06390956
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
NCT06544265
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT05990465
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Incyte Corporation
NCT04680052
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT03162536
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Reid Merryman, MD
NCT05783596
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT02339922
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
NCT04464200
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03884998
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04212013
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04416451
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Children's Oncology Group
NCT01000753
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Gilead Sciences
NCT01282424
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03833180
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics
NCT01980628
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00880815
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
NCT00644189
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT05169658
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co.
NCT04018248
Imexon for Relapsed Follicular and Aggressive Lymphomas
University of Rochester
NCT01314014
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics
NCT03364231
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Cancer Institute (NCI)
NCT04599634
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 20 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Marginal Zone Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Marginal Zone Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Marginal Zone Lymphoma page
50 registered trials, 28 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 28 Marginal Zone Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Marginal Zone Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Marginal Zone Lymphoma condition card totals 50 registered trials; most-linked intervention Rituximab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.